Lung Cancer Medicare Access to Precise Testing Act

# Lung Cancer Medicare Access to Precise Testing Act (HR 6321) **What the Bill Would Do** This bill would expand Medicare coverage for genetic and molecular testing in lung cancer patients. Specifically, it would ensure that Medicare covers advanced diagnostic tests that identify specific mutations or characteristics in lung cancer tumors. These tests help doctors determine which targeted treatments are most likely to work for an individual patient's cancer, allowing for more personalized medicine approaches. **Who It Affects** The bill primarily affects Medicare beneficiaries (typically seniors age 65+) diagnosed with lung cancer. It would also impact healthcare providers and hospitals that treat these patients, as well as diagnostic testing companies.

By expanding what tests Medicare will pay for, the bill could improve treatment outcomes for older Americans with lung cancer while potentially increasing healthcare costs. **Current Status** As of now, HR 6321 is in committee, meaning it has been introduced but has not yet been debated or voted on by the full House of Representatives. The bill was sponsored by Rep. Josh Gottheimer (D-NJ).